U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07151326) titled 'Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy' on Aug. 14.
Brief Summary: 1. To investigate the efficacy and safety of cabozantinib in patients with progressive HCC after ICI-based combination treatment.
2. To explore potential tissue and peripheral blood biomarkers associated with clinical benefits of cabozantinib, and resistance mechanisms of prior ICI and cabozantinib.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Carcinoma (HCC)
Intervention:
DRUG: Cabozantinib
All patients will be treated with cabozantinib at 60 mg once daily.
Recruitment Stat...